logo-loader
viewMotif Bio PLC

Motif Bio gets confirmation of requirements for new iclaprim trial

Motif has now received the minutes of its Type B meeting with the US Food and Drug Administration in September

Motif Bio PLC -

Motif Bio PLC (LON:MTFB) has received official confirmation of the parameters of a new trial to get US approval for its iclaprim antibiotic.

Minutes of a Type B meeting between Motif and US Food and Drug Administration in September indicated a single well-designed adequate and well-controlled Phase III clinical trial demonstrating safety and efficacy of iclaprim in patients with bacterial pneumonia (HABP/VABP), along with data on potential mechanisms of hepatic injury, would enable submission of a New Drug Application.

Motif Bio repeated that it would take several years to enrol and complete a HABP/VABP Phase III trial and cost tens of millions of dollars hence its decision to either find a partner to pay for the trial or else dispose of iclaprim to a firm with deeper pockets.

The FDA is concerned about possible liver toxicity with iclaprim, something that emerged following the submission of trial data from two phase III assessments of the drug.

Graham Lumsden, chief executive, said: "We now have confirmation of what will be required to progress iclaprim towards a potential approval.

"The company is working hard to find a partner or other entity to complete the HABP/VABP Phase III trial, commercialise iclaprim and ensure the best outcome for shareholders in Motif Bio."

Quick facts: Motif Bio PLC

Price: 0.265 GBX

AIM:MTFB
Market: AIM
Market Cap: £1.29 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: AfriTin Mining produces first concentrate from Uis mine

Headlines from the Proactive UK newsroom. AfriTin Mining (LON:ATM) has produced is first tin concentrate from the Uis mine in Namibia. The miner has also signed an offtake deal with a Thai group.  BlueRock Diamonds (LON:BRD) has sold a fifth diamond this year for more than US$50,000....

on 19/8/19

RNS

Second Price Monitoring Extn

3 days, 14 hours ago

Price Monitoring Extension

3 days, 14 hours ago

Holding(s) in Company

1 week, 2 days ago

Second Price Monitoring Extn

1 week, 3 days ago

Price Monitoring Extension

1 week, 3 days ago

Second Price Monitoring Extn

1 week, 3 days ago

Price Monitoring Extension

1 week, 3 days ago

Holding(s) in Company

1 week, 5 days ago

2 min read